tetano
Editor, Senior Moderator
Br J Haematol
. 2020 Jul 31.
doi: 10.1111/bjh.17050. Online ahead of print.
Thrombolysis restores perfusion in COVID 19 hypoxia
Deepa J Arachchillage[SUP] 1 2 3 [/SUP], Arthur Stacey[SUP] 2 [/SUP], Frances Akor[SUP] 4 [/SUP], Martin Scotz[SUP] 5 [/SUP], Mike Laffan[SUP] 1 2 [/SUP]
Affiliations
Abstract
Thrombolysis with tissue plasminogen activator (tPA) is an established treatment strategy for patients with intermediate and high-risk pulmonary embolism (PE) and signs of haemodynamic instability. The use of tPA in coronavirus disease -19 (COVID-19) patients with PE and acute respiratory distress syndrome (ARDS) may be of benefit due to the unusually high incidence of pulmonary embolism and pulmonary thrombosis, particularly microvascular thrombosis which are thought to contribute significantly to hypoxemia(1).
. 2020 Jul 31.
doi: 10.1111/bjh.17050. Online ahead of print.
Thrombolysis restores perfusion in COVID 19 hypoxia
Deepa J Arachchillage[SUP] 1 2 3 [/SUP], Arthur Stacey[SUP] 2 [/SUP], Frances Akor[SUP] 4 [/SUP], Martin Scotz[SUP] 5 [/SUP], Mike Laffan[SUP] 1 2 [/SUP]
Affiliations
- PMID: 32735730
- DOI: 10.1111/bjh.17050
Abstract
Thrombolysis with tissue plasminogen activator (tPA) is an established treatment strategy for patients with intermediate and high-risk pulmonary embolism (PE) and signs of haemodynamic instability. The use of tPA in coronavirus disease -19 (COVID-19) patients with PE and acute respiratory distress syndrome (ARDS) may be of benefit due to the unusually high incidence of pulmonary embolism and pulmonary thrombosis, particularly microvascular thrombosis which are thought to contribute significantly to hypoxemia(1).